Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 3, 2008, Pages 918-925

  Leamon, Christopher P ^a   Reddy, Joseph A ^a   Dorton, Ryan ^a   Bloomfield, Alicia ^a   Emsweller, Kristen ^a   Parker, Nikki ^a   Westrick, Elaine ^a  

^a Endocyte Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLATE RECEPTOR; FOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DIETARY INTAKE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG ERYTHROCYTE LEVEL; FEMALE; FOLIC ACID BLOOD LEVEL; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; VITAMIN SUPPLEMENTATION;

ANIMALS; CARRIER PROTEINS; DIET; DRUG DELIVERY SYSTEMS; FOLIC ACID; HUMANS; MICE; NEOPLASMS; RECEPTORS, CELL SURFACE; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57349181510     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.143206     Document Type: Article

References (41)

1. Antony AC (1992) The biological chemistry of folate receptors. Blood 79:2807-2820.
2. Antony AC (1996) Folate receptors. Annu Rev Nutr 16:501-521.
3. Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, et al. (2007) A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin Cancer Res 13:2692-2698.
4. Birn H, Nielsen S, and Christensen EI (1997) Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule. Am J Physiol 272: F70-F78.
5. Branda RF, Chen Z, Brooks EM, Naud SJ, Trainer TD, and McCormack JJ (2002) Diet modulates the toxicity of cancer chemotherapy in rats. J Lab Clin Med 140:358-368.
6. Clifford AJ, Arjomand A, Dueker SR, Schneider PD, Buchholz BA, and Vogel JS (1998) The dynamics of folic acid metabolism in an adult given a small tracer dose of 14C-folic acid. Adv Exp Med Biol 445:239-251.
7. Corrocher R, De Sandre G, Pacor ML, and Hoffbrand AV (1974) Hepatic protein binding of folate. Clin Sci Mol Med 46:551-554.
8. Covello KL, Flefleh C, Menard K, Wiebesiek A, Mcglinchey K, Wen ML, Westhouse R, Reddy JA, Vlahov IR, Hunt J, et al. (2008) Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development, in Proceedings of the 99th Annual Meeting of American Association for Cancer Research; 2008 April 12-16; San Diego, CA. Abstract 2326, American Association for Cancer Research, Philadelphia, PA.
9. da Costa M, Rothenberg SP, Sadasivan E, Regec A, and Qian L (2000) Folate deficiency reduces the GPI-anchored folate binding protein in rat renal tubules. Am J Physiol Cell Physiol 278:C812-C821.
10. Fernandes-Costa F and Metz J (1979) Role of serum folate binders in the delivery of folate to tissues and to the fetus. Br J Haematol 41:335-342.
11. Fisher RE, Siegel BA, Edell SL, Oyesiku NM, Morgenstern DE, Messmann RA, and Amato RJ (2008) Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 49:899-906.
12. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, and Zalipsky S (2003) In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 9:6551-6559.
13. Gates SB, Mendelsohn LG, Shackelford KA, Habeck LL, Kursar JD, Gossett LS, Worzalla JF, Shih C, and Grindey GB (1996) Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression. Clin Cancer Res 2:1135-1141.
14. Holm J, Hansen SI, Høier-Madsen M, and Bostad L (1992) A high affinity folate binding protein in proximal tubule cells of human kidney. Kidney Int 41:50-55.
15. Kamen BA, Wang MT, Streckfuss AJ, Peryea X, and Anderson RGW (1988) Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem 263:13602-13609.
16. Klipstein FA and Lipton SD (1970) Intestinal flora of folate-deficient mice. Am J Clin Nutr 23:132-140.
17. Leamon CP and Low PS (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 88:5572-5576.
18. 99mTc-based radiopharmaceutical. Bioconj Chem 13:1200-1210.
19. Leamon CP and Reddy JA (2004) Folate-targeted chemotherapy. Adv Drug Deliv Rev 56:1127-1141.
20. Leamon CP, Reddy JA, Vlahov IR, Kleindl PJ, Vetzel M, and Westrick E (2006) Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate. Bioconjug Chem 17:1226-1232.
21. Leamon CP, Reddy JA, Vlahov IR, Vetzel M, Parker N, Nicoson JS, Xu LC, and Westrick E (2005) Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjug Chem 16:803-811.
22. Leamon CP, Reddy JA, Vlahov IR, Westrick E, Dawson A, Dorton R, Vetzel M, Santhapuram HK, and Wang Y (2007a) Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 4:659-667.
23. Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, and Vetzel M (2007b) Comparative preclinical activity of the folate-targeted vinca alkaloid conjugates EC140 and EC145. Int J Cancer 121:1585-1592.
24. Lennard L, Lilleyman JS, and Maddocks JL (1986) The effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukaemia. Br J Cancer 53:115-119.
25. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, and Green MA (1996) Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med 37:1003-1008.
26. Mendelsohn LG, Gates SB, Habeck LL, Shackelford KA, Worzalla J, Shih C, and Grindey GB (1996) The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Adv Enzyme Regul 36:365-381.
27. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, and Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284-293.
28. Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J, and Sampson EJ (2005) Biochemical indicators of b vitamin status in the US population after folic acid fortification: results from the national health and nutrition examination survey 1999-2000. Am J Clin Nutr 82:442-450.
29. Raghunathan K, Schmitz JC, and Priest DG (1997) Disposition of leucovorin and its metabolites in dietary folic acid-deplete mice-comparison between tumor, liver, and plasma. Cancer Chemother Pharmacol 40:126-130.
30. Reddy JA, Dorton R, Bloomfield A, Emsweller K, Vetzel M, Wang Y, Santhapuram HK, Kleindl P, You F, Vlahov IR, et al. (2008) Comparative pre-clinical evaluations of highly potent and specific folate-tubulysin conjugates, in Proceedings of the 99th Annual Meeting of American Association for Cancer Research; 2008 April 12-16; San Diego, CA. Abstract 1414, American Association for Cancer Research, Philadelphia, PA.
31. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, and Leamon CP (2007a) Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 67:4434-4442.
32. Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, Vlahov I, Chari RV, Goldmacher VS, and Leamon CP (2007b) Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res 67: 6376-6382.
33. Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, and Leamon CP (2006) Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol 58:229-236.
34. Reddy JA, Xu LC, Parker N, Vetzel M, and Leamon CP (2004) Preclinical evaluation of (99m)tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 45:857-866.
35. Rubinoff M, Abramson R, Schreiber C, and Waxman S (1981) Effect of a folate-binding protein on the plasma transport and tissue distribution of folic acid. Acta Haematol 65:145-152.
36. Sausville E, LoRusso P, Quinn M, Forman K, Leamon C, Morganstern D, Bever S, and Messmann R (2007) A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors (abstract 2577). Proceedings of the American Society of Clinical Oncology 25:18S.
37. Venn BJ, Mann JI, Williams SM, Riddell LJ, Chisholm A, Harper MJ, Aitken W, and Rossaak JI (2002) Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomised placebo-controlled double-blind dietary intervention trial. Eur J Clin Nutr 56:748-754.
38. Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, and Leamon CP (2006) Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 16:5093-5096.
39. Vlahov IR, Santhapuram HK, Wang Y, Kleindl PJ, You F, Howard SJ, Westrick E, Reddy JA, and Leamon CP (2007) An assembly concept for the consecutive introduction of unsymmetrical disulfide bonds: synthesis of a releasable multidrug conjugate of folic acid. J Org Chem 72:5968-5972.
40. Vlahov IR, Wang Y, Vetzel M, Hahn S, Reddy JA, and Leamon CP (2008) Synthetic modifications of natural tubulysins and in vivo evaluation of their cytotoxicity, in Proceedings of the 99th Annual Meeting of American Association for Cancer Research; 2008 April 12-16; San Diego, CA. Abstract 2261, American Association for Cancer Research, Philadelphia, PA.
41. Worzalla JF, Shih C, and Schultz RM (1998) Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res 18:3235-3239.